SCPH — Scpharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $168.01m
- $130.81m
- $13.59m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 13.6 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 9.78 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 32.9 | 29.9 | 25.8 | 36.2 | 69 |
Operating Profit | -32.9 | -29.9 | -25.8 | -36.2 | -55.4 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -33 | -32.2 | -28 | -36.8 | -54.8 |
Net Income After Taxes | -33 | -32.2 | -28 | -36.8 | -54.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -33 | -32.2 | -28 | -36.8 | -54.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33 | -32.2 | -28 | -36.8 | -54.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.77 | -1.31 | -1.14 | -1.3 | -1.42 |